



The real risk in life sciences?

Neglecting to evolve compliance programs

By Jeffrey Garfield, Managing Director,
Life Sciences Advisory, KPMG LLP



Over the past decade, compliance programs at life sciences companies have grown in scope and complexity. Now, executives and boards of directors are questioning whether these larger programs are effectively reducing their risks, or have they become too onerous to deliver real business value?



Many drivers toward complexity

Key stakeholders within compliance, legal, and internal audit at major life sciences organizations are becoming increasingly concerned about the effectiveness of their global compliance programs. Most recognize that these programs have become increasingly complex and are seeing their workloads rise as the business and regulatory environments evolve. And they are concerned that they may not be protecting against risks in a manner that meets the needs of the organization.

The recent wave of industry convergence has led many life sciences organizations to explore new market segments and business models. Service- and solution-based business models have emerged as players vie for competitive advantage. And this has forced compliance leaders to not only come to grips with new requirements, but also grapple with massive questions about efficiently integrating disparate business models into existing compliance programs.

At the same time, the shift toward value-based payment models creates new concerns and complexities. Key stakeholders are assessing how the new models will change sales and marketing approaches and interactions with group purchasing organizations, payers, healthcare organizations, and healthcare professionals. And they are thinking about how shared risk and bundled payments will impact their current compliance processes and policies.

Of course, all of this sits against a backdrop of continued pressures for cost reduction and efficiency and an uncertain political climate. Life sciences organizations continue to ask their compliance functions to do more. But they are asking them to do it without increasing cost or head count. This is the compliance conundrum, and only time will tell how organizations will respond.

Compliance functions are out of synch

With pressure now mounting for change, many compliance leaders are taking a critical look at their functions and related areas of focus. And what they are finding is that they have become outdated—and in some cases, oversized.

The problem is that—in the pursuit of achieving a “gold standard” of compliance (as laid out by various enforcement actions, deferred prosecution agreements, and corporate integrity agreements)—they have allowed their functions to grow in size and complexity. However, changes are often not aligned with the internal risk tolerance of the company or emerging trends in the regulatory and political landscape.

Each new regulatory enforcement action, new or updated guidance document, merger, or acquisition has spawned new processes and policies that are layered over the top of existing compliance frameworks.

Most compliance functions are now suffering from significant overlap and redundancy, as well as outdated requirements that fail to mitigate the intended risk or effect a change in behavior within the business to align with the risk tolerance of the company. Most important, valuable resources are soaked up chasing down insignificant infractions and policing the policy.

Three hallmarks of successful programs

Not surprisingly, many of the leading compliance functions across the United States and around the world are now rethinking their approaches to delivering on objectives. And while each is taking a customized approach to transforming its compliance programs and revisiting its strategies, our experience suggests that the most successful programs aim for three main outcomes:



1. Becoming more practical

Key stakeholders are challenging the status quo and questioning the realized value of their programs in comparison to strategic compliance and commercial objectives. They recognize they will never have a perfect program and are, therefore, sharpening their focus on identifying and addressing the right risks for their particular business and markets. This, in turn, has allowed them to realign their resources to focus on higher-priority areas that create significant risks for the business.



2. Realigning responsibility

Rather than enforcing a policy-driven program, many of the leading organizations are now shifting toward a principles-based program that essentially shifts responsibility for compliance back to the business. They are recognizing that compliance is an everyday priority that should be ingrained within all levels of the company. And so, they are giving the business the guidance, training, and support required to achieve compliance and allowing them to adapt the processes to their daily jobs. In doing so, they are spending less time policing the business and more time on their own business objectives.



3. Focusing resources

Leading organizations are finding opportunities to release their resources from low-value tasks. Some are leveraging data analytics to improve efficiency and reduce manual processes. Others are rationalizing processes to eliminate duplication. The key is that these resources are now being tasked to higher-value activities that focus on the most important risks and critical processes for the business. They do not see this as an opportunity to cut costs but rather as a way to improve the overall impact of compliance efforts and increase alignment with the go-forward strategy of the company.

Case Study:

A life sciences company shifts its compliance strategy

KPMG LLP (KPMG) recently worked with a multinational life sciences manufacturer that boasts hundreds of compliance officers and a sterling reputation for compliance excellence. While the organization was content with their progress, key stakeholders were concerned that recent changes to their operating models and regulatory requirements had changed the need to address risks within their compliance program.

Our review found that the organization did, indeed, face a number of unanticipated risks related to anti-bribery and corruption, privacy, government pricing, off-label usage, and cybersecurity. There was particular concern about international operations and growth efforts that were not being properly managed. Monitoring was not optimized, so resources were being wasted creating and reviewing point-in-time and static reports rather than anticipating and reacting to future and current risks.

With an improved view of their most critical risks, the organization was able to shift their resources to tasks that delivered the highest value to the organization. They pushed accountability for compliance monitoring back down to the business and are currently exploring new technology solutions to help improve the timeliness of monitoring for the business. As a result, they have improved value, enhanced efficiency, and reduced complexity for themselves and their organization.

Taking the first steps toward change

Organizations just beginning this journey should not be daunted by the task at hand. This is not about wholesale transformation or disruptive change but rather about making smart and incremental changes that lead to a new approach for the enterprise.

Key legal, internal audit, and compliance stakeholders may want to start by taking five fairly simple steps to help define their future models and capabilities.

- 1 Identify the real risks.** Work with an independent adviser to capture a more realistic view of the risk environment throughout the business and industry. Assess the future risks that may occur as a result of new business models (particularly services and solutions), mergers and acquisitions, and value-based payment models. Review the existing risk registry to assess relative risk and its impact on your current business strategy.
- 2 Conduct a review of your current-state compliance program.** Identify areas of duplication and low efficiency as they relate to actual or perceived risks. Consider how processes can be rationalized to improve productivity and reduce friction within the business.
- 3 Talk to your commercial constituents.** Take the time to understand how current policies and procedures are impacting the commercial team, and test new ideas and processes with them. Ensure that all policy and process decisions are made with the input and buy-in of those that will be held accountable for it. These changes can be facilitated by compliance champions from within the business.
- 4 Consider the value of technology.** From robotic process automation to improved visualization to predictive analytics, assess how your organization might leverage new technologies to improve efficiency and reduce risks. Remember that data only has value if it is focused on a clear business problem, resultant action, and user base.
- 5 Review the training approach.** Rather than a checkbox exercise, consider how training can be made more impactful as the organization shifts toward principles-based compliance. Help the business and third-parties understand why policies are in place and how to adhere to them. Provide a “blueprint for success” and show what good looks like to help your employees and third-parties understand and implement the spirit of the policy.

About KPMG

KPMG helps life sciences organizations further develop and enhance their compliance programs with the intent to help increase effectiveness and efficiency, expand compliance integration, and enhance strategic business decision making.

KPMG's services are customized according to your organization's regulatory requirements, objectives, business, operations, and jurisdictional reach. We help organizations fundamentally reassess and retool their compliance governance, compliance culture, and business and risk operations. This includes helping our clients align their compliance programs to the specific requirements of their industry and jurisdiction, anticipating regulatory changes, and understanding the practices of their peers.

Contact us




Ajay Sanganeria

Partner, Life Sciences
KPMG in Singapore
+65 6213 2292
asanganeria@kpmg.com.sg



Jareen Yao

Director, Life Sciences
KPMG in Singapore
+65 6411 8133
jareenyao@kpmg.com.sg



Jeffrey Garfield

Managing Director,
Life Sciences Advisory
317-616-2520
jeffreygarfield@kpmg.com



Alison Little

Advisory Industry Leader,
Life Sciences
973-912-4611
jalittle@kpmg.com

To learn more about KPMG's Healthcare and Life Sciences practice, please visit us at:
www.kpmg.com/us/healthcarelifesciences.

Some or all of the services described herein may not be permissible for KPMG audit clients and their affiliates.

The information contained herein is of a general nature and is not intended to address the circumstances of any particular individual or entity. Although we endeavor to provide accurate and timely information, there can be no guarantee that such information is accurate as of the date it is received or that it will continue to be accurate in the future. No one should act upon such information without appropriate professional advice after a thorough examination of the particular situation.

© 2017 KPMG LLP, a Delaware limited liability partnership and the U.S. member firm of the KPMG network of independent member firms affiliated with KPMG International Cooperative ("KPMG International"), a Swiss entity. All rights reserved. NDPPS 633040

The KPMG name and logo are registered trademarks or trademarks of KPMG International.

kpmg.com/socialmedia

